MT1G, an emerging ferroptosis‐related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer

• DOI: 10.1002/tox.23997
• Publication Date: 2023-11-17T08:17:13Z
• Authors: Bisheng Cheng; Yiming Lai; Hao Huang; Shirong Peng; Chen Tang; Junxiu Chen; Tianlong Luo; Jilin Wu; Haixia He; Qiong Wang; Hai Huang

Background Prostate cancer is a leading cause of cancer-related deaths in men worldwide. Despite advances treatment strategies, there still need for novel therapeutic targets and approaches. Ferroptosis has emerged as critical process the development progression several cancers, including prostate (PCA). In this study, we investigate role MT1G, gene implicated immune responses ferroptosis, pathogenesis PCA. Our objective to elucidate its prognostic significance impact on tumor microenvironment, while exploring potential enhancing sensitivity checkpoint inhibitor (ICI) therapy. Methods We utilized combination silico analysis experimental techniques MT1G First, analyzed large-scale genomic datasets assess expression pattern PCA patients. Subsequently, performed functional assays explore involvement modulating responses. addition, conducted vivo experiments evaluate effect growth response ICI Results revealed that significantly downregulated tissues compared normal associated with poor prognosis. Furthermore, overexpression inhibited cells vitro vivo. Importantly, found regulates microenvironment by cell infiltration inhibiting immunosuppressive factors. our study reveals significant correlation between levels therapy (PCA) patients, upregulation leads an increase PDL-1 expression. These findings underscore promising predictive biomarker Conclusion elucidates pivotal played profound implications Moreover, it raises intriguing possibility could pave way approaches treatment. This arises from ability orchestrate within consequently Therefore, hold substantial promise advancing comprehension innovative strategies.